AMLX (STOCKS)
Amylyx Pharmaceuticals, Inc. Common Stock
$22.480000
-0.870000 (-3.73%)
Prev close: $23.350000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Joshua B. Cohen
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $2,898.41M
- Employees
- 123
- P/E (TTM)
- -16.30
- P/B (TTM)
- 10.87
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
8
Strong Buy
7
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Jun 2026 (Q2)
|
$-0.39 | $-0.37 | -0.0219 | -5.95% |
|
Mar 2026 (Q1)
|
$-0.37 | $-0.34 | -0.0331 | -9.82% |
|
Dec 2025 (Q4)
|
$-0.30 | $-0.37 | +0.0660 | +18.03% |
|
Sep 2025 (Q3)
|
$-0.37 | $-0.46 | +0.0889 | +19.37% |
Financial Statements
| Revenues | $0.00 |
| Costs And Expenses | $162.10M |
| Nonoperating Income/Loss | $10.06M |
| Selling, General, and Administrative Expenses | $69.66M |
| Research and Development | $92.45M |
| Operating Income/Loss | -$162.10M |
| Income/Loss From Continuing Operations After Tax | -$152.09M |
| Income/Loss From Continuing Operations Before Tax | -$154.32M |
| Net Income/Loss | -$152.09M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$152.09M |
| Net Income/Loss Available To Common Stockholders, Basic | -$152.09M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.41 |
| Diluted Earnings Per Share | -$1.41 |
| Basic Average Shares | 209,362,864 |
| Diluted Average Shares | 209,362,864 |
| Assets | $264.56M |
| Current Assets | $256.34M |
| Noncurrent Assets | $8.23M |
| Fixed Assets | $199.00K |
| Other Non-current Assets | $8.03M |
| Liabilities | $25.40M |
| Current Liabilities | $21.15M |
| Accounts Payable | $5.53M |
| Wages | $5.63M |
| Other Current Liabilities | $9.99M |
| Noncurrent Liabilities | $4.25M |
| Equity | $239.17M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $239.17M |
| Liabilities And Equity | $264.56M |
| Net Cash Flow From Operating Activities | -$126.58M |
| Net Cash Flow From Operating Activities, Continuing | -$126.58M |
| Net Cash Flow From Investing Activities | -$78.83M |
| Net Cash Flow From Investing Activities, Continuing | -$78.83M |
| Net Cash Flow From Financing Activities | $196.09M |
| Net Cash Flow From Financing Activities, Continuing | $196.09M |
| Exchange Gains/Losses | $90.00K |
| Net Cash Flow | -$9.22M |
| Net Cash Flow, Continuing | -$9.31M |
| Comprehensive Income/Loss | -$152.46M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$152.62M |
| Other Comprehensive Income/Loss | -$78.18M |
| Other Comprehensive Income/Loss Attributable To Parent | -$531.00K |